statins also known hmgcoa reductase inhibitors class lipidlowering medications reduce illness mortality high risk cardiovascular commonly prescribed cholesterollowering drugs lowdensity lipoprotein ldl carriers cholesterol play key role development atherosclerosis coronary heart disease via mechanisms described lipid hypothesis statins effective lowering ldl cholesterol widely used primary prevention people high risk cardiovascular disease well secondary prevention developed cardiovascular side effects statins include muscle pain increased risk diabetes mellitus abnormal blood levels certain liver additionally rare severe adverse effects particularly muscle damage rarely act inhibiting enzyme hmgcoa reductase plays central role production cholesterol high cholesterol levels associated cardiovascular various forms statins include atorvastatin fluvastatin lovastatin pitavastatin pravastatin rosuvastatin combination preparations statin another agent ezetimibesimvastatin also available class world health organizations list essential medicines simvastatin listed sales estimated billion united bestselling statin atorvastatin also known lipitor became bestselling pharmaceutical manufacturer pfizer reported sales billion patient compliance statin usage problematic many medical practitioners despite robust evidence benefits majority statins usually used lower blood cholesterol levels reduce risk illnesses related atherosclerosis varying degree effect depending underlying risk factors history cardiovascular disease clinical practice guidelines generally recommend people start lifestyle modification cholesterollowering diet physical exercise unable meet lipidlowering goals methods statins medication appears work equally well regardless although sexrelated differences treatment response underlying history cardiovascular disease significant impact effects statin used divide medication usage broad categories primary secondary primary prevention cardiovascular disease united states preventive services task force uspstf guidelines recommend statins least one risk factor coronary heart disease years old least risk heart disease calculated accaha pooled cohort risk factors coronary heart disease included abnormal lipid levels blood diabetes mellitus high blood pressure recommended selective use lowtomoderate doses statins adults calculated cardiovascular disease event risk people age statins decrease risk cardiovascular disease history heavy cholesterol blockage evidence suggests statins also effective preventing heart disease high cholesterol history heart disease cochrane review found decrease risk death poor outcomes without evidence every people treated years one fewer dies every treated one fewer episode heart review reached similar review found benefits women review concluded treatment without history cardiovascular disease reduces cardiovascular events men women provides mortality benefit either two metaanalyses published year one used data obtained exclusively women found mortality benefit primary national institute health clinical excellence nice recommends statin treatment adults estimated year risk developing cardiovascular disease greater guidelines american college cardiology american heart association recommend statin treatment primary prevention cardiovascular disease adults ldl cholesterol mgdl diabetes age ldlc mgdl risk developing heart attack stroke latter group statin assignment automatic recommended occur clinicianpatient risk discussion shared decision making risk factors lifestyle addressed potential benefit statin weighed potential adverse effects drug interactions informed patient preference elicited moreover risk decision uncertain factors family history coronary calcium score anklebrachial index inflammation test hscrp mgl suggested inform risk decision additional factors could used ldlc high lifetime however critics steven e nissen say ahaacc guidelines properly validated overestimate risk least recommend statins people benefit based populations whose observed risk lower predicted european society cardiology european atherosclerosis society recommend use statins primary prevention depending baseline estimated cardiovascular score ldl statins effective decreasing mortality people preexisting cardiovascular preexisting disease many manifestations defining illnesses include prior heart attack stroke stable unstable angina aortic aneurysm arterial ischemic disease presence also advocated use people high risk developing coronary heart average statins lower ldl cholesterol mmoll mgdl translates estimated decrease number cardiac events heart attack sudden cardiac death reduced risk stroke longterm greater benefit observed highintensity statin less effect fibrates niacin reducing triglycerides raising hdlcholesterol good studies examined effect statins cognition patients prior stroke however two large studies hps prosper included people vascular diseases reported simvastatin pravastatin impact statins studied improving operative outcomes cardiac vascular mortality adverse cardiovascular events reduced statin older adults receive statin therapy time discharge hospital inpatient stay studied people cardiac ischemia previously statins time admission lower risk major cardiac adverse events hospital readmission two years statins appear effective regardless potency degree cholesterol simvastatin pravastatin appear reduced incidence according cochrane systematic review atorvastatin showed greater cholesterollowering effect women men compared children statins effective reducing cholesterol levels familial long term safety however recommend lifestyle changes enough statins started years statins may less effective reducing ldl cholesterol people familial hypercholesterolemia especially homozygous people defects usually either ldl receptor apolipoprotein b genes responsible ldl clearance statins remain firstline treatment familial although cholesterolreducing measures may people homozygous deficiencies statins may still prove helpful albeit high doses combination cholesterolreducing metaanalysis found statins could reduce risk contrastinduced nephropathy people undergoing coronary angiographypercutaneous interventions effect found stronger among preexisting kidney dysfunction diabetes asthma statins identified possible adjunct role treatment asthma though antiinflammatory cochrane review found low quality evidence use statins asthma therefore could draw conclusions effectiveness important adverse side effects muscle problems increased risk diabetes mellitus increased liver enzymes blood due liver years treatment statins result cases diabetes cases bleeding stroke cases muscle damage per people could due statins inhibiting enzyme hmgcoa reductase necessary make cholesterol also processes production important muscle function sugar possible adverse effects include pancreatic liver dysfunction sexual rate events occur widely debated part riskbenefit ratio statins lowrisk populations highly dependent rate adverse cochrane metaanalysis statin clinical trials primary prevention found evidence excess adverse events among treated statins compared another metaanalysis found increase adverse events statin treated people relative receiving placebo increase serious adverse author one study argued adverse events common clinical practice randomized clinical systematic review concluded clinical trial metaanalyses underestimate rate muscle pain associated statin use rates rhabdomyolysis still reassuringly low similar seen clinical trials per person another systematic review international centre circulatory health national heart lung institute london concluded small fraction side effects reported people statins actually attributable multiple systematic reviews metaanalyses concluded available evidence support association statin use cognitive statins shown decrease risk dementia alzheimers disease improve cognitive impairment cases update additionally patientcentered research outcomes stroke patients prefer effectiveness research prosper health protection study hps demonstrated simvastatin pravastatin affect cognition patients risk factors history vascular reports reversible cognitive impairment us food drug administration fda package insert statins includes warning potential nonserious reversible cognitive side effects medication memory loss observational studies people take statins experience muscle problems cases consist muscle rates much higher seen randomized clinical topic extensive debate muscle symptoms often cause patients stop taking known statin intolerance recent randomized controlled trial gave statinintolerant patients statin placebo inside capsules looked making study doubleblind participants know taking period statin placebo repeated times periods random order patients queried symptoms similar statin placebo showing statin intolerance depends people knowing theyre taking statin smaller doubleblind rct obtained similar shown symptom scores majority participants studies intended restart statin treatment results studies help explain statin symptom rates observational studies much higher doubleblind rcts difference results nocebo effect opposite placebo effect symptoms caused expectations media reporting statins often negative patient leaflets inform patients rare potentially serious muscle problems occur statin treatment create expectations harm nocebo symptoms real bothersome major barrier treatment many people stop taking proven numerous largescale rcts reduce heart attacks stroke long people continue take serious muscle problems rhabdomyolysis destruction muscle cells statinassociated autoimmune myopathy occur less treated rhabdomyolysis turn result lifethreatening kidney injury risk statininduced rhabdomyolysis increases older age use interacting medications fibrates coenzyme ubiquinone levels decreased statin supplements sometimes used treat statinassociated myopathy though evidence efficacy lacking gene solute carrier organic anion transporter family member codes organic aniontransporting polypeptide involved regulation absorption statins common variation gene found significantly increase risk records exist people treated statin drugs atorvastatin cerivastatin fluvastatin lovastatin pravastatin incidence rhabdomyolysis per patients treated statins cerivastatin however risk greater cerivastatin used standard statins atorvastatin fluvastatin lovastatin pravastatin simvastatin combined fibrate fenofibrate gemfibrozil treatment cerivastatin withdrawn manufacturer researchers suggested hydrophilic statins fluvastatin rosuvastatin pravastatin less toxic lipophilic statins atorvastatin lovastatin simvastatin studies found lovastatin induces expression gene believed responsible promoting muscle fiber tendon rupture appear relationship statin use risk developing diabetes remains unclear results reviews higher doses greater effect decrease cardiovascular disease outweighs risk developing use postmenopausal women associated increased risk exact mechanism responsible possible increased risk diabetes mellitus associated statin use however recent findings indicated inhibition hmgcoar key statins thought decrease cells uptake glucose bloodstream response hormone one way thought occur interfering cholesterol synthesis necessary production certain proteins responsible glucose uptake cells several metaanalyses found increased risk cancer metaanalyses found reduced specifically statins may reduce risk esophageal colorectal gastric hepatocellular possibly prostate appear effect risk lung kidney breast pancreatic bladder combining statin fibrate niacin categories lipidlowering drugs increases risks rhabdomyolysis almost per monitoring liver enzymes creatine kinase especially prudent highdose statins statinfibrate combinations mandatory case muscle cramps deterioration kidney functioncitation needed consumption grapefruit grapefruit juice inhibits metabolism certain statins bitter oranges may similar furanocoumarins grapefruit juice ie bergamottin dihydroxybergamottin inhibit cytochrome enzyme involved metabolism statins however major inhibitor lovastatin simvastatin lesser degree atorvastatin flavonoids ie naringin thought responsible increases levels statin increasing risk doserelated adverse effects including myopathyrhabdomyolysis absolute prohibition grapefruit juice consumption users statins us food drug administration fda notified healthcare professionals updates prescribing information concerning interactions protease inhibitors certain statin drugs protease inhibitors statins taken together may increase blood levels statins increase risk muscle injury myopathy serious form myopathy rhabdomyolysis damage kidneys lead kidney failure studies found use statins may protect getting osteoporosis fractures may induce osteoporosis crosssectional retrospective analysis entire austrian population found risk getting osteoporosis dependent dose statin consumption connected increased prevalence statins act competitively inhibiting hmgcoa reductase ratelimiting enzyme mevalonate pathway statins similar structure hmgcoa molecular level fit enzymes active site compete native substrate hmgcoa competition reduces rate hmgcoa reductase able produce mevalonate next molecule cascade eventually produces cholesterol variety natural statins produced penicillium aspergillus fungi secondary metabolites natural statins probably function inhibit hmgcoa reductase enzymes bacteria fungi compete inhibiting hmgcoa reductase statins block pathway synthesizing cholesterol liver significant circulating cholesterol comes internal manufacture rather diet liver longer produce cholesterol levels cholesterol blood fall cholesterol synthesis appears occur mostly statins short halflives usually taken night maximize effect studies shown greater ldl total cholesterol reductions shortacting simvastatin taken night rather shown difference longacting rabbits liver cells sense reduced levels liver cholesterol seek compensate synthesizing ldl receptors draw cholesterol accomplished via proteases cleave membranebound sterol regulatory element binding proteins migrate nucleus bind sterol response elements sterol response elements facilitate increased transcription various proteins notably ldl receptor ldl receptor transported liver cell membrane binds passing ldl vldl particles mediating uptake liver cholesterol reprocessed bile salts byproducts results net effect less ldl circulating blood statins inhibiting hmg coa reductase pathway inhibit downstream synthesis isoprenoids farnesyl pyrophosphate geranylgeranyl pyrophosphate inhibition protein prenylation proteins rhoa subsequent inhibition rhoassociated protein kinase may involved least partially improvement endothelial function modulation immune function pleiotropic cardiovascular benefits well fact number drugs lower ldl shown cardiovascular risk benefits studies may also account benefits seen cancer reduction addition inhibitory effect protein prenylation may also involved number unwanted side effects associated statins including muscle pain elevated blood sugar noted statins exhibit action beyond lipidlowering activity prevention atherosclerosis socalled pleiotropic effects pleiotropic effects statins remain asteroid trial showed direct ultrasound evidence atheroma regression statin researchers hypothesize statins prevent cardiovascular disease via four proposed mechanisms subjects large body biomedical jupiter trial showed statins provided benefit history high cholesterol heart disease elevated highsensitivity creactive protein hscrp levels indicator study criticized due perceived flaws study although paul ridker lead investigator jupiter trial responded criticisms click genes proteins metabolites link respective articles target statins hmgcoa reductase highly similar eukaryota archaea statins also act antibiotics archaea inhibiting archaeal mevalonate biosynthesis shown vivo since patients constipation phenotype present higher abundance methanogenic archaea gut use statins management irritable bowel syndrome proposed may actually one hidden benefits statin statins divided two groups fermentationderived synthetic specific types listed table note associated brand names may vary countries ldllowering potency varies agents cerivastatin potent withdrawn market august due risk serious rhabdomyolysis followed order decreasing potency rosuvastatin atorvastatin simvastatin lovastatin pravastatin relative potency pitavastatin yet fully established preliminary studies indicate potency similar types statins naturally occurring found foods oyster mushrooms red yeast rice randomized controlled trials found foodstuffs reduce circulating cholesterol quality trials judged due patent expiration blockbuster branded statins generic since including atorvastatin largestsellingcitation needed branded medical citation needed role cholesterol development cardiovascular disease elucidated second half lipid hypothesis prompted attempts reduce cardiovascular disease burden lowering cholesterol treatment consisted mainly dietary measures lowfat diet poorly tolerated medicines clofibrate cholestyramine nicotinic acid cholesterol researcher daniel steinberg writes coronary primary prevention trial demonstrated cholesterol lowering could significantly reduce risk heart attacks angina physicians including cardiologists remained largely scientists academic settings pharmaceutical industry began trying develop drug reduce cholesterol effectively several potential targets steps synthesis cholesterol acetylcoenzyme akira endo japanese biochemist working pharmaceutical company sankyo began investigate problem research already shown cholesterol mostly manufactured body liver enzyme hmgcoa endo team reasoned certain microorganisms may produce inhibitors enzyme defend organisms mevalonate precursor many substances required organisms maintenance cell walls cytoskeleton first agent identified mevastatin molecule produced fungus penicillium citrinum british group isolated compound penicillium brevicompactum named compactin published report british group mentions antifungal properties mention hmgcoa reductase inhibitionmedical citation needed mevastatin never marketed adverse effects tumors muscle deterioration sometimes death laboratory dogs p roy vagelos chief scientist later ceo merck co interested made several trips japan starting merck isolated lovastatin mevinolin fungus aspergillus terreus first marketed result public campaigns people united states became familiar cholesterol numbers difference hdl ldl cholesterol various pharmaceutical companies began producing statins pravastatin pravachol manufactured sankyo bristolmyers squibb april results mercksponsored study scandinavian simvastatin survival study announced researchers tested simvastatin later sold merck zocor patients high cholesterol heart disease five years study concluded patients saw reduction cholesterol chances dying heart attack reduced zocor mevacor made merck though profit original discovery endo awarded japan prize laskerdebakey clinical medical research award pioneering endo also inducted national inventors hall fame alexandria virginia michael brown joseph goldstein nobel prize related work cholesterol said endo millions people whose lives extended statin therapy owe akira misleading claims exaggerating adverse effects statins received widespread media coverage consequent negative impact public controversy effectiveness statins medical literature amplified popular media early leading estimated people uk stop using statins sixmonth period mid according authors study funded british heart foundation estimated could extra heart attacks strokes following years unintended effect academic statin controversy spread scientifically questionable alternative therapies cardiologist steven nissen cleveland clinic commented losing battle hearts minds patients web promoting unproven medical therapies harriet hall sees spectrum statin denialism ranging pseudoscientific claims understatement benefits overstatement side effects contrary scientific several statins approved generic drugs united states clinical studies conducted use statins lung nuclear prostate breast high quality evidence statins useful small number available trials support use statins adjunctive therapy monotherapy multiple httpsenwikipediaorgwikistatin